NCT04696055 2025-05-13Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint InhibitorsBayerPhase 2 Completed95 enrolled 14 charts